Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price grew 91.62% from a year ago, while it registered an 80.98% increase year-to-date. On April 16, Vir Biotechnology announced the closing of its global collaboration and licensing agreement with Astellas following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The collaboration aims to accelerate the development of VIR-5500, a pro ...